ECM
CRSP icon

EagleClaw Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

EagleClaw Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$930K Buy
+17,050
New +$899K 0.12% 96

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EagleClaw Capital Management's CRSP Position: Q2 2026 in Review

EagleClaw Capital Management opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 17,050 shares worth $930K. The stake represents 0.12% of the portfolio and ranks #96 among its holdings.

521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • EagleClaw Capital Management held 17,050 shares of CRISPR Therapeutics worth $930K as of Q2 2026.
  • CRISPR Therapeutics was a new EagleClaw Capital Management position in Q2 2026.
  • CRISPR Therapeutics made up 0.12% of EagleClaw Capital Management's portfolio in Q2 2026, its #96 holding.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on EagleClaw Capital Management's 13F filing for Q2 2026, filed 10 Aug 2026.